This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Dosing
Dose Adjustments & Escalations
Tab Number 3
Tab Number 4
Tab Number 5
The recommended dose of BOSULIF for pediatric patients with newly diagnosed CP Ph+ CML is 300 mg/m2 orally once daily with food
The recommended dosage for pediatric patients with CP Ph+ CML that is resistant or intolerant to prior therapy is 400 mg/m2 orally once daily with food. Dose recommendations are provided below
As appropriate, the desired dose can be attained by combining different strengths of BOSULIF tablets or capsules
The recommended dosage is taken orally once daily with food.
Tablets
Do not cut, crush, break, or chew tablets.
Capsules
Capsules may be swallowed whole
Mixing the capsule contents with applesauce or yogurt cannot be considered a substitute for a proper meal
For patients who are unable to swallow capsules, the contents of the capsules can be mixed with applesauce or yogurt.
Remove the required number of capsules from the container to prepare the dose as instructed and the amount of either room-temperature applesauce or yogurt in a clean container
Carefully open each capsule, add the entire capsule content of each capsule into the applesauce or yogurt, then mix the entire dose into the applesauce or yogurt
Patients should immediately consume the full mixture in its entirety, without chewing. Do not store the mixture for later use. If the entire preparation is not swallowed, do not take an additional dose. Wait until the next day to resume dosing
In pediatric patients, dose adjustments for nonhematologic toxicities can be conducted similarly to adults (see Therapy Management); however, the dose reduction increments may differ.
For pediatric patients with BSA <1.1 m2, reduce dose by 50 mg initially, followed by additional 50-mg increment if the adverse reaction persists
For pediatric patients with BSA ≥1.1 m2 or greater, reduce dose similarly to adults
In pediatric patients with BSA <1.1 m2 and an insufficient response after 3 months, consider increasing dose by 50-mg increments, up to maximum of 100 mg above starting dose
Dose increases for insufficient response in pediatric patients with BSA ≥1.1 m2 can be conducted similarly to adult recommendations, in 100-mg increments
The maximum dose in pediatric and adult patients is 600 mg once daily
Bosutinib is a tyrosine kinase inhibitor
The MyTherapy® App includes a section dedicated to BOSULIF patients to support them with medication reminders, treatment tracking, and helpful resources
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy
BOSULIF is indicated for the treatment of:
Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy